U.S. High Intensity Focused Ultrasound Therapy Market Size, Share & Forecast 2026–2032

ID: MR-11708 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: High Intensity Focused Ultrasound Therapy
  • ✓Market Size 2024: USD 412 million
  • ✓Market Size 2032: USD 1.08 billion
  • ✓CAGR: 12.8%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Reimbursement Sequencing Determines Adoption: Insightec's Exablate Neuro dominates the essential tremor installed base because its FDA indication preceded broad Medicare payment clarity. Prostate ablation vendors like Profound Medical face the reverse sequence, slowing hospital capital decisions.
FINDING 02
Neurology Not Oncology Drives Growth: The consensus holds that prostate cancer ablation will drive U.S. focused ultrasound growth. The evidence points to neuromodulation instead, as BRAIN Initiative-funded research moves focused ultrasound toward depression, epilepsy, and Alzheimer's trials, expanding the addressable neurology base beyond tremor.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Pre-Coverage Capital Planning: Hospital capital buyers should engage Medicare Administrative Contractors and CMS TCET applicants before the 2026 budget cycle closes. Secure documented CPT 55880 reimbursement pathways before committing to an Exablate or TULSA-PRO purchase, because unreimbursed installs erode margin within 18 months.

Focused Ultrasound Therapy in the U.S.: Market Overview

The U.S. high intensity focused ultrasound therapy market was valued at USD 412 million in 2024 and is projected to reach USD 1.08 billion by 2032. Its shape is set by Food and Drug Administration premarket approval under Section 515 of the Federal Food, Drug, and Cosmetic Act, which gates each therapeutic indication. Insightec's Exablate Neuro, approved for essential tremor and later Parkinson's disease tremor, anchors the neurology segment, while FDA-cleared prostate ablation systems form the urology base.

Private manufacturers have led commercialization, with Profound Medical's TULSA-PRO and SonaCare Medical's Sonablate competing for urology capital budgets across academic centers. Government has been the dominant force in funding the science, as National Institutes of Health grants and the BRAIN Initiative underwrote early clinical trials that preceded device approvals. The result is a market where public research funding created the evidence base and private firms converted it into installed systems.

Policy-Driven Growth in the U.S. Focused Ultrasound Market

Three policy mechanisms are converting clinical evidence into procedure volume. First, FDA premarket approval under Section 515 of the Federal Food, Drug, and Cosmetic Act grants legally marketable indications, and each new indication opens a separately reimbursable clinical population. Second, Medicare payment for CPT code 55880, which covers transrectal HIFU prostate ablation, is set through the CMS Hospital Outpatient Prospective Payment System, and that rate determines whether urology departments purchase systems.

Third, the CMS Transitional Coverage for Emerging Technologies pathway allows conditional Medicare coverage with evidence development for devices that meet breakthrough criteria, shortening the gap between FDA approval and national payment. Manufacturers holding FDA Breakthrough Device designation under Section 515B can enter TCET, which reduces the commercial lag that previously kept focused ultrasound systems in research settings for years after approval. This mechanism raises utilization of essential tremor and Parkinson's tremor procedures among Medicare-age patients.

Regulatory Barriers and Compliance Costs

Premarket review is the first barrier. The FDA's Center for Devices and Radiological Health reviews original PMA submissions under MDUFA V performance goals, with a target of 180 FDA review days for 90 percent of decisions. Clinical trial design requires investigational device exemption approval under 21 CFR Part 812 and institutional review board oversight under 21 CFR Part 56, typically adding 12 to 24 months before PMA submission.

State certificate-of-need laws create the second barrier. New York's Public Health Law Article 28 requires New York State Department of Health approval before hospitals acquire high-cost imaging-guided systems, and comparable regimes in Massachusetts and North Carolina add state review delays. The third barrier is quality compliance: the Quality Management System Regulation, amending 21 CFR Part 820 to align with ISO 13485:2016, takes effect February 2, 2026, requiring manufacturers to revalidate design controls.

Policy-Created Opportunities in U.S. Focused Ultrasound

Veterans Health Administration procurement offers a concrete opening. The VA's National Acquisition Center issues national contracts for medical devices, and VA medical centers treating tremor and Parkinson's patients form a volume buyer that can absorb systems without awaiting a Medicare coverage decision. Manufacturers securing national contract listings gain a federal reference customer that shortens hospital procurement cycles across the wider network.

NIH and BRAIN Initiative funding creates a second opportunity in neuromodulation. Focused ultrasound research is testing non-invasive modulation for depression, epilepsy, and Alzheimer's disease, and trials that obtain Breakthrough Device designation can enter TCET, which accelerates Medicare coverage for the resulting indication. Developers with early neuromodulation pipelines can target this pathway ahead of competitors lacking clinical data.

Market at a Glance

MetricValue
Market Size 2024USD 412 million
Market Size 2032USD 1.08 billion
Growth Rate (CAGR)12.8%
Most Critical Decision FactorReimbursement coverage and FDA indication scope
Largest RegionNortheast census region
Competitive StructureConcentrated, with few vendors holding most installed systems

Leading Market Participants

  • Insightec
  • Profound Medical
  • SonaCare Medical
  • EDAP TMS
  • Focus Surgery
  • GE HealthCare
  • Siemens Healthineers
  • Philips
  • Canon Medical Systems
  • Theraclion

Regulatory and Policy Environment

The primary device legislation is the Federal Food, Drug, and Cosmetic Act of 1938 as amended by the Medical Device Amendments of 1976, which created premarket approval under Section 515 and classification under Section 510(k). The Food and Drug Administration administers it through the Center for Devices and Radiological Health. Key compliance requirements include PMA supplements for new indications, post-approval study obligations under 21 CFR Part 814, Medical Device Reporting under 21 CFR Part 803, and Unique Device Identification under 21 CFR Part 830.

Upcoming changes include the QMSR taking effect February 2, 2026, and MDUFA V expiring September 30, 2027, so MDUFA VI reauthorization must precede that date. Compared with the EU Medical Device Regulation (EU) 2017/745, the U.S. PMA route demands randomized evidence for novel therapies but delivers faster reimbursement pathways. Japan's PMDA requires local clinical data, while China's NMPA has approved domestic HIFU systems through a faster domestic pathway.

Long-Term Policy Outlook for Focused Ultrasound in the U.S.

By 2032, MDUFA VI will set FDA review goals for the next five-year period, and those performance commitments will determine whether focused ultrasound neuromodulation indications reach market within current timelines. CMS is expected to extend conditional coverage to additional indications as the TCET pathway accumulates completed coverage decisions. Each decision will expand the reimbursable population for Parkinson's tremor and neuromodulation.

Medicare site-neutral payment policy under annual OPPS rulemaking will likely move HIFU procedures from inpatient to ambulatory settings, lowering per-case costs and expanding procedure volume in ambulatory surgical centers. Hospitals that have invested in inpatient capacity will face margin pressure, while outpatient operators that secure early Medicare rate clarity will capture the expanded volume. Policy timing will therefore determine which care settings lead adoption through 2032.

Frequently Asked Questions

Most therapeutic focused ultrasound systems require premarket approval under Section 515 of the Federal Food, Drug, and Cosmetic Act. Some prostate ablation systems entered the market through 510(k) clearance instead.
CPT code 55880 covers transrectal HIFU prostate ablation and is paid through the CMS Hospital Outpatient Prospective Payment System. Hospitals should confirm coverage with their local Medicare Administrative Contractor before purchase.
TCET allows conditional Medicare coverage for devices with FDA Breakthrough Device designation, shortening the gap between approval and national payment. Coverage carries evidence development requirements that manufacturers must fund.
The Quality Management System Regulation amends 21 CFR Part 820 to align with ISO 13485:2016, effective February 2, 2026. Manufacturers must update design control and documentation systems to meet the revised requirements.
Certificate-of-need laws in states such as New York, Massachusetts, and North Carolina can require state approval before hospitals acquire high-cost systems. Hospitals in these states should factor review timelines into capital planning.

Market Segmentation

By Application
  • Essential Tremor
  • Parkinson's Disease Tremor
  • Prostate Cancer Ablation
  • Uterine Fibroid Ablation
  • Neuromodulation Research
By End User
  • Academic Medical Centers
  • Community Hospitals
  • Ambulatory Surgical Centers
  • Veterans Affairs Medical Centers
By Technology
  • MR-Guided Focused Ultrasound
  • Ultrasound-Guided HIFU
  • Transrectal HIFU Systems
  • Transcranial Focused Ultrasound

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Focused Ultrasound Therapy - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Application Insights
4.1 Essential Tremor
4.2 Parkinson's Disease Tremor
4.3 Prostate Cancer Ablation
4.4 Uterine Fibroid Ablation
4.5 Others
Chapter 05 End User Insights
5.1 Academic Medical Centers
5.2 Community Hospitals
5.3 Ambulatory Surgical Centers
5.4 Veterans Affairs Medical Centers
5.5 Others
Chapter 06 Technology Insights
6.1 MR-Guided Focused Ultrasound
6.2 Ultrasound-Guided HIFU
6.3 Transrectal HIFU Systems
6.4 Transcranial Focused Ultrasound
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Insightec
7.2.2 Profound Medical
7.2.3 SonaCare Medical
7.2.4 EDAP TMS
7.2.5 Focus Surgery
7.2.6 GE HealthCare
7.2.7 Siemens Healthineers
7.2.8 Philips
7.2.9 Canon Medical Systems
7.2.10 Theraclion
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.